- Home
- FBRT vs PHAT Comparison
FBRT vs PHAT Comparison
Compare FBRT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRT
- PHAT
- Stock Information
- Founded
- FBRT 2012
- PHAT 2018
- Country
- FBRT United States
- PHAT United States
- Employees
- FBRT N/A
- PHAT N/A
- Industry
- FBRT Real Estate Investment Trusts
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- FBRT Real Estate
- PHAT Health Care
- Exchange
- FBRT Nasdaq
- PHAT Nasdaq
- Market Cap
- FBRT 882.8M
- PHAT 942.6M
- IPO Year
- FBRT 1985
- PHAT 2019
- Fundamental
- Price
- FBRT $9.96
- PHAT $14.55
- Analyst Decision
- FBRT Strong Buy
- PHAT Strong Buy
- Analyst Count
- FBRT 4
- PHAT 5
- Target Price
- FBRT $14.75
- PHAT $17.60
- AVG Volume (30 Days)
- FBRT 743.3K
- PHAT 955.8K
- Earning Date
- FBRT 10-29-2025
- PHAT 10-30-2025
- Dividend Yield
- FBRT 14.20%
- PHAT N/A
- EPS Growth
- FBRT N/A
- PHAT N/A
- EPS
- FBRT 0.80
- PHAT N/A
- Revenue
- FBRT $241,051,000.00
- PHAT $147,190,000.00
- Revenue This Year
- FBRT $24.35
- PHAT $218.38
- Revenue Next Year
- FBRT $7.16
- PHAT $87.14
- P/E Ratio
- FBRT $12.52
- PHAT N/A
- Revenue Growth
- FBRT 32.77
- PHAT 460.30
- 52 Week Low
- FBRT $9.78
- PHAT $2.21
- 52 Week High
- FBRT $13.58
- PHAT $16.08
- Technical
- Relative Strength Index (RSI)
- FBRT 34.90
- PHAT 63.09
- Support Level
- FBRT $9.78
- PHAT $13.79
- Resistance Level
- FBRT $10.20
- PHAT $14.22
- Average True Range (ATR)
- FBRT 0.21
- PHAT 1.04
- MACD
- FBRT -0.02
- PHAT 0.07
- Stochastic Oscillator
- FBRT 16.67
- PHAT 58.36
About FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.